West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est

West Pharmaceutical Servs (NYSE: WST ) raises FY2026 Adj EPS guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 analyst estimate. Raises FY2026 sales outlook from $3.295 billion-$3.350 billion to $3.345 billion-$3.380 billion vs $3.332 billion estimate.